CoChat
Sign Up
Cited by 69Ovarian function and disordersPharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome

Diamanti‐Kandarakis, Evanthia, Katsikis, Ilias, Piperi, Christina, Alexandraki, Krystallenia, Panidis, Dimitrios·2007·Clinical Endocrinology
DOI 10.1111/j.1365-2265.2006.02693.x
Open this paper in CoChat — free account

Abstract

UNLABELLED: BACKGROUND Women with polycystic ovary syndrome (PCOS) exhibit elevated serum advanced glycation end-products (AGE) compared with healthy subjects. Short-term administration of orlistat has been shown to reduce the postmeal increase in serum AGE levels in women with PCOS and in controls. OBJECTIVE: To evaluate the long-term effect of orlistat and a low-calorie diet on serum AGE levels, and on the hormonal and metabolic profile of obese PCOS and normal women. DESIGN: A clinical trial of 6 months of orlistat administration with an energy-restricted diet [basic metabolic rate (BMR) 600 kcal/day] in all subjects. SUBJECTS: Twenty-nine women with PCOS [aged 27.52 +/- 5.77 years; body mass index (BMI) 35.43 +/- 5.31 kg/m(2)] and 18 controls (aged 32.06 +/- 5.64 years; BMI 36.39 +/- 6.47 kg/m(2)). MEASUREMENTS: Serum AGE levels (U/ml), hormonal and metabolic profile. RESULTS: PCOS and controls did not differ in BMI (P = 0.58), waist-to-hip ratio (WHR) (P = 0.44), fasting insulin concentration (P = 0.45) and glucose-to-insulin ratio (GIR) (P = 0.34). PCOS women exhibited statistically higher AGE (P < 0.001) and testosterone levels (P < 0.001) compared with controls. After 6 months of orlistat treatment, AGE levels showed a statistically significant decrease in both groups (PCOS: baseline 9.08 +/- 1.84, post-orlistat 8.56 +/- 1.95, P = 0.001; controls: baseline 5.02 +/- 0.62, post-orlistat 4.91 +/- 0.69, P = 0.03), independently of the BMI reduction in the PCOS group. A significant reduction was observed in BMI (PCOS: P < 0.001; controls: P < 0.001), WHR (PCOS: P = 0.002; controls: P = 0.04), fasting insulin (PCOS: P < 0.001; controls: P = 0.008), and testosterone concentrations in PCOS (P < 0.001). SHBG concentration (PCOS: P = 0.004; controls: P = 0.008) and GIR (PCOS: P < 0.001; controls: P = 0.03) were significantly increased. A significant improvement was also observed in insulin resistance indices post-treatment in both groups. CONCLUSIONS: Our data suggest that orlistat has a beneficial effect in reducing elevated AGE levels and improving the hormonal and metabolic profile in women with PCOS after 6 months of treatment, independently of BMI changes.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2006.02693.x

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • One study with a hypocaloric diet + anti-obesity drug (Orlistat) intervention reported a statistically significant difference in SHBG between groups (p < 0.05) following the intervention; however, there was also a statistically significant difference in SHBG at baseline between the groups (p < 0.05).

    “One study with a hypocaloric diet + anti-obesity drug (Orlistat) intervention [30] reported a statistically significant difference between groups (p < 0.05) following the intervention; however, there was also a statistically significant difference in SHBG at baseline between the groups (p < 0.05).”

    From Weight management interventions in women with and without PCOS: a systematic review (2017) · cites this paper as [30]

  • One study with a hypocaloric diet + an anti-obesity drug intervention (Orlistat), and another study with an anti-obesity drug intervention (Orlistat) + a hypocaloric diet + exercise intervention, reported a statistically significant difference in total testosterone following intervention between the two study groups, with the non-PCOS group having lower values in both studies.

    “One study with a hypocaloric diet + an anti-obesity drug intervention (Orlistat) [30], and another study with an anti-obesity drug intervention (Orlistat) + a hypocaloric diet + exercise intervention [35] reported a statistically significant difference in total testosterone following intervention between the two study groups, with the non-PCOS group having lower values in both studies (Table 3).”

    From Weight management interventions in women with and without PCOS: a systematic review (2017) · cites this paper as [30]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Diamanti‐Kandarakis, E., Katsikis, I., Piperi, C., Alexandraki, K., & Panidis, D.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Aristotle University of Thessaloniki (GR)
Corresponding author
Diamanti‐Kandarakis, Evanthia
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2006-10-31
Volume
66
Issue
1
Pages
103-109
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1111/j.1365-2265.2006.02693.x
OpenAlex
W2117396309
Cited by
69
References
43
Citations by year
2025: 1 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 5 · 2013: 4 · 2012: 7
FWCI
4.89
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
polycystic ovary syndrome, orlistat, advanced glycation end products, hypocaloric diet, obesity, testosterone, insulin resistance, glucose-to-insulin ratio, weight loss, lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, fasting insulin, waist-to-hip ratio, body mass index, women's health, metabolic profile, hormonal profile
MeSH terms
Orlistat, Adult, Blood Glucose, Diet, Drug Administration Schedule, Female, Humans, Insulin, Lactones, Lipase, Obesity, Polycystic Ovary Syndrome, Sex Hormone-Binding Globulin, Testosterone, Time Factors, Body Mass Index, Linear Models, Case-Control Studies, Glycation End Products, Advanced, Anti-Obesity Agents, Waist-Hip Ratio

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review